This was the stock's third consecutive day of losses.

Edwards Lifesciences stock rose slightly late Tuesday on strong sales of its TAVR procedures, leading to a top- and bottom-line beat.

Edwards Lifesciences Corp. engages in the patient-focused medical innovations for heart disease and critical care monitoring. Its products are categorized into three areas: Transcatheter Heart ...

Sigma Planning Corp reduced its stake in Edwards Lifesciences Co. (NYSE:EW – Free Report) by 6.5% during the 4th quarter, according to its most recent filing with the Securities and Exchange ...

Edwards Lifesciences Corp. closed 21.12% short of its 52-week high of $96.12, which the company reached on March 28th.

IRVINE, Calif., February 25, 2025--Edwards Lifesciences Corporation (NYSE: EW) today announced it will participate in the TD Cowen 45th Annual Health Care Conference on Tuesday, Mar. 4 ...

Edwards Lifesciences Corporation (NYSE:EW), a leading medical technology company specializing in heart valve therapies and critical care technologies with a market capitalization of $44.9 billion, has ...

Investment analysts at Leerink Partnrs lowered their Q1 2025 earnings per share estimates for shares of Edwards Lifesciences in a research report issued on Wednesday, February 12th. Leerink Partnrs ...

We sell different types of products and services to both investment professionals and individual investors. These products and services are usually sold through license agreements or subscriptions ...

Edwards Lifesciences’ EW fourth-quarter performance was backed by its most comprehensive structural heart disease portfolio. The Surgical Structural Heart business is benefiting from the strong ...